Financial Consequences of the Act on Reimbursement of Medicines for the National Health Fund and Patients

The aim of the paper is to present the financial consequences of the entry into force of the Reimbursement Act in 2012 for the National Health Fund, a payer of public funds, and for individual patients. A greater burden on the society – i.e. an increase in the level of co-payment for medicines – turns out to be integrated in the general tendency that emerges during the economic crisis in many European countries at different levels of socio-economic development.

Abstract licence: CC BY-NC-ND

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.